Phase I study in Patients with solid tumours
Study identifier:D8180C00023
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase I, Open-label Study to assess the safety and tolerability of AZD0530 in combination with Carboplatin and/or Paclitaxel chemotherapy in patients with solid tumours
Medical condition
Neoplasms
Phase
Phase 1
Healthy volunteers
No
Study drug
AZD0530, Carboplatin, Paclitaxel
Sex
All
Actual Enrollment
148
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Mar 2007
Primary Completion Date: 01 Jan 2010
Study Completion Date: 01 Mar 2010
Study design
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 AZD0530 + Paclitaxel | Drug: AZD0530 oral tablet Other Name: n/a Drug: Paclitaxel intravenous infusion |
| Experimental: 2 AZD0530 + Carboplatin | Drug: AZD0530 oral tablet Other Name: n/a Drug: Carboplatin intravenous infusion |
| Experimental: 3 AZD0530 + Carboplatin + Paclitaxel | Drug: AZD0530 oral tablet Other Name: n/a Drug: Carboplatin intravenous infusion Drug: Paclitaxel intravenous infusion |
Contacts
Investigators
Principal Investigator
Steinar Aamdal
Radium Hospital, Norway
